Why Icatibant Injection?

Treatment Times Two

Help your patients be prepared to treat HAE attacks by suggesting they carry Icatibant Injection with them at all times.

  • The guidelines1,8 recommend that your patients should have two on-demand HAE treatments available at all times.
  • Fresenius Kabi’s FDA-approved, generic Icatibant Injection provides patients with an option in treating acute attacks of Hereditary angioedema (HAE).
  • Icatibant Injection is supplied as a 3 mL prefilled, single use syringe and is available in both single- and three-syringe packages.

When to Use Icatibant Injection11

Icatibant Injection can be used to treat all acute HAE attacks, including cutaneous, abdominal, and laryngeal attacks. Instruct patients to take Icatibant Injection at the first sign of symptoms or as soon as possible after they start. Icatibant Injection can reduce the duration and time to resolution of the attack.

Icatibant Injection is appropriate for adults 18 years of age and older with HAE Type I or Type II, including patients who are taking preventive therapy.

Offer Your HAE Patients a Convenient, Easy-to-use Treatment

Fresenius Kabi’s generic Icatibant Injection is a convenient, subcutaneous treatment that gives patients the freedom to live confidently. Icatibant Injection is indicated for the treatment of acute attacks of Hereditary angioedema (HAE) in adults 18 years of age and older.

Fresenius Kabi’s Icatibant Injection is the generic self-administered, subcutaneous injection for the acute treatment of HAE attacks. The prefilled syringe requires:

  • NO reconstitution/mixing
  • NO dose calculation
  • NO dose titration
  • NO refrigeration

Fresenius Kabi’s Icatibant Injection single-use syringe should be stored between 2°C – 25°C (36°F – 77°F). Do not freeze. Store in carton until time of administration. Patients may self-administer Fresenius Kabi’s generic Icatibant Injection after proper administration training by a healthcare professional.

People who experience an HAE attack of the throat should seek immediate medical attention, even after taking an on-demand therapy.

Dosing and Administration11

  • 30 mg per 3 mL
  • concentration is 10 mg per mL
  • 25 gauge needle
  • Single use prefilled syringe

Icatibant injection is supplied in a prefilled syringe delivering 30 mg icatibant. Each syringe delivers 3 mL solution with a concentration of 10 mg per mL.

The recommended dose of Icatibant Injection is 30 mg administered by subcutaneous (SC) injection in the abdominal area at the first signs of attack symptoms. Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur. No more than 3 doses may be administered in any 24-hour period.

How Icatibant Injection Works

Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production.

Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.

Untreated HAE patient during an attack

HAE patient after Icatibant Injection treatment

After Icatibant Injection is administered, the drug attaches to the B2 receptor, blocking bradykinin from attaching to it and thereby preventing further vasodilation.

Potential Side Effects of Icatibant Injection11

The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References

  • [1] Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3.
  • [8] Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990.
  • [11] Icatibant Injection Prescribing Information. Fresenius Kabi USA, LLC; 2020.

*FIRAZYR® is a registered trademark of Shire, a Takeda company.